Stephen Squinto, chief investment officer and managing partner for JP Morgan Life Sciences Private Capital

Stephen Squin­to talks writ­ing checks and next-gen obe­si­ty drugs as JP Mor­gan clos­es first $500M+ biotech fund

Over a year and a half since its in­cep­tion, JP Mor­gan’s life sci­ences in­vest­ment arm has closed its first biotech ven­ture cap­i­tal fund with over …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.